The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors.
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals
Honoraria - Novartis; Novartis; Novartis
Consulting or Advisory Role - Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - Novartis; Novartis; Novartis
 
Yoon-Koo Kang
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Bayer; Novartis; Roche/Genentech
 
John R. Weis
No Relationships to Disclose
 
Glynn Weldon Gilcrease
No Relationships to Disclose
 
Cynthia Davidson
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Novartis
 
Rachel Kingsford
No Relationships to Disclose
 
Joan Collett
No Relationships to Disclose
 
Nicole Orgain
No Relationships to Disclose
 
Min-Hee Ryu
Honoraria - Novartis; Roche Pharma AG
Consulting or Advisory Role - Novartis; Roche Pharma AG
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Sook Ryun Park
No Relationships to Disclose
 
Hee-Won Yoo
Employment - Bukwang Pharmaceutical
Stock and Other Ownership Interests - Bukwang Pharmaceutical
 
Sung-Chul Kim
Employment - Labceutics
Leadership - Labceutics
Stock and Other Ownership Interests - Labceutics